vs
Apellis Pharmaceuticals, Inc.（APLS）与Clearway Energy, Inc.（CWEN）财务数据对比。点击上方公司名可切换其他公司
Clearway Energy, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.6倍（$310.0M vs $199.9M），Apellis Pharmaceuticals, Inc.净利率更高（-29.5% vs -33.5%，领先4.1%），Clearway Energy, Inc.同比增速更快（21.1% vs -5.9%），Clearway Energy, Inc.自由现金流更多（$71.0M vs $-14.3M），过去两年Clearway Energy, Inc.的营收复合增速更高（8.6% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
NRG能源是总部位于美国得克萨斯州休斯敦的能源企业，前身为后续更名为埃克西尔能源的北方州电力公司的批发业务板块，2000年独立运营。业务覆盖发电与电力零售，拥有天然气、煤炭、石油、核能、风电、公用事业级及分布式太阳能等发电资产，服务超700万零售用户。
APLS vs CWEN — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $310.0M |
| 净利润 | $-59.0M | $-104.0M |
| 毛利率 | — | 51.9% |
| 营业利润率 | -25.6% | -11.9% |
| 净利率 | -29.5% | -33.5% |
| 营收同比 | -5.9% | 21.1% |
| 净利润同比 | -62.2% | -3566.7% |
| 每股收益（稀释后） | $-0.40 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $310.0M | ||
| Q3 25 | $458.6M | $429.0M | ||
| Q2 25 | $178.5M | $392.0M | ||
| Q1 25 | $166.8M | $298.0M | ||
| Q4 24 | $212.5M | $256.0M | ||
| Q3 24 | $196.8M | $486.0M | ||
| Q2 24 | $199.7M | $366.0M | ||
| Q1 24 | $172.3M | $263.0M |
| Q4 25 | $-59.0M | $-104.0M | ||
| Q3 25 | $215.7M | $236.0M | ||
| Q2 25 | $-42.2M | $33.0M | ||
| Q1 25 | $-92.2M | $4.0M | ||
| Q4 24 | $-36.4M | $3.0M | ||
| Q3 24 | $-57.4M | $36.0M | ||
| Q2 24 | $-37.7M | $51.0M | ||
| Q1 24 | $-66.4M | $-2.0M |
| Q4 25 | — | 51.9% | ||
| Q3 25 | — | 70.2% | ||
| Q2 25 | — | 66.6% | ||
| Q1 25 | — | 59.1% | ||
| Q4 24 | — | 52.0% | ||
| Q3 24 | — | 72.2% | ||
| Q2 24 | — | 68.0% | ||
| Q1 24 | — | 52.1% |
| Q4 25 | -25.6% | -11.9% | ||
| Q3 25 | 48.7% | 26.1% | ||
| Q2 25 | -18.6% | 21.7% | ||
| Q1 25 | -50.0% | — | ||
| Q4 24 | -12.3% | -14.5% | ||
| Q3 24 | -24.0% | 36.6% | ||
| Q2 24 | -14.7% | 23.0% | ||
| Q1 24 | -36.0% | -11.0% |
| Q4 25 | -29.5% | -33.5% | ||
| Q3 25 | 47.0% | 55.0% | ||
| Q2 25 | -23.6% | 8.4% | ||
| Q1 25 | -55.3% | 1.3% | ||
| Q4 24 | -17.1% | 1.2% | ||
| Q3 24 | -29.2% | 7.4% | ||
| Q2 24 | -18.9% | 13.9% | ||
| Q1 24 | -38.5% | -0.8% |
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | — | ||
| Q2 25 | $-0.33 | — | ||
| Q1 25 | $-0.74 | — | ||
| Q4 24 | $-0.30 | — | ||
| Q3 24 | $-0.46 | — | ||
| Q2 24 | $-0.30 | — | ||
| Q1 24 | $-0.54 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $231.0M |
| 总债务越低越好 | — | $7.9B |
| 股东权益账面价值 | $370.1M | $5.8B |
| 总资产 | $1.1B | $16.7B |
| 负债/权益比越低杠杆越低 | — | 1.36× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $231.0M | ||
| Q3 25 | $479.2M | $251.0M | ||
| Q2 25 | $370.0M | $260.0M | ||
| Q1 25 | $358.4M | $297.0M | ||
| Q4 24 | $411.3M | $332.0M | ||
| Q3 24 | $396.9M | $292.0M | ||
| Q2 24 | $360.1M | $226.0M | ||
| Q1 24 | $325.9M | $478.0M |
| Q4 25 | — | $7.9B | ||
| Q3 25 | — | $8.1B | ||
| Q2 25 | — | $8.3B | ||
| Q1 25 | — | $7.2B | ||
| Q4 24 | — | $6.8B | ||
| Q3 24 | — | $6.7B | ||
| Q2 24 | — | $6.8B | ||
| Q1 24 | $93.1M | $7.6B |
| Q4 25 | $370.1M | $5.8B | ||
| Q3 25 | $401.2M | $5.7B | ||
| Q2 25 | $156.3M | $5.5B | ||
| Q1 25 | $164.2M | $5.4B | ||
| Q4 24 | $228.5M | $5.6B | ||
| Q3 24 | $237.1M | $5.6B | ||
| Q2 24 | $264.3M | $5.7B | ||
| Q1 24 | $266.7M | $5.0B |
| Q4 25 | $1.1B | $16.7B | ||
| Q3 25 | $1.1B | $16.1B | ||
| Q2 25 | $821.4M | $16.0B | ||
| Q1 25 | $807.3M | $14.6B | ||
| Q4 24 | $885.1M | $14.3B | ||
| Q3 24 | $901.9M | $14.2B | ||
| Q2 24 | $904.5M | $14.5B | ||
| Q1 24 | $831.9M | $14.9B |
| Q4 25 | — | 1.36× | ||
| Q3 25 | — | 1.41× | ||
| Q2 25 | — | 1.49× | ||
| Q1 25 | — | 1.33× | ||
| Q4 24 | — | 1.21× | ||
| Q3 24 | — | 1.20× | ||
| Q2 24 | — | 1.19× | ||
| Q1 24 | 0.35× | 1.50× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $177.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $71.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 22.9% |
| 资本支出强度资本支出/营收 | 0.1% | 34.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $369.0M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $177.0M | ||
| Q3 25 | $108.5M | $225.0M | ||
| Q2 25 | $4.4M | $191.0M | ||
| Q1 25 | $-53.4M | $95.0M | ||
| Q4 24 | $19.4M | $192.0M | ||
| Q3 24 | $34.1M | $301.0M | ||
| Q2 24 | $-8.3M | $196.0M | ||
| Q1 24 | $-133.0M | $81.0M |
| Q4 25 | $-14.3M | $71.0M | ||
| Q3 25 | $108.3M | $144.0M | ||
| Q2 25 | $4.4M | $115.0M | ||
| Q1 25 | $-53.4M | $39.0M | ||
| Q4 24 | $19.3M | $142.0M | ||
| Q3 24 | — | $266.0M | ||
| Q2 24 | $-8.4M | $92.0M | ||
| Q1 24 | $-133.3M | $-17.0M |
| Q4 25 | -7.1% | 22.9% | ||
| Q3 25 | 23.6% | 33.6% | ||
| Q2 25 | 2.5% | 29.3% | ||
| Q1 25 | -32.0% | 13.1% | ||
| Q4 24 | 9.1% | 55.5% | ||
| Q3 24 | — | 54.7% | ||
| Q2 24 | -4.2% | 25.1% | ||
| Q1 24 | -77.3% | -6.5% |
| Q4 25 | 0.1% | 34.2% | ||
| Q3 25 | 0.0% | 18.9% | ||
| Q2 25 | 0.0% | 19.4% | ||
| Q1 25 | 0.0% | 18.8% | ||
| Q4 24 | 0.0% | 19.5% | ||
| Q3 24 | 0.0% | 7.2% | ||
| Q2 24 | 0.0% | 28.4% | ||
| Q1 24 | 0.2% | 37.3% |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 0.95× | ||
| Q2 25 | — | 5.79× | ||
| Q1 25 | — | 23.75× | ||
| Q4 24 | — | 64.00× | ||
| Q3 24 | — | 8.36× | ||
| Q2 24 | — | 3.84× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CWEN
暂无分部数据
